Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial

AIMS: To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin. MATERIALS AND METHODS: A randomized, multicentre, double‐blind, double‐dummy, active‐controlled trial across 86 office‐ or hospital‐based sites in North America, Euro...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Diabetes Obes Metab
Hoofdauteurs: Bailey, T. S., Takács, R., Tinahones, F. J., Rao, P. V., Tsoukas, G. M., Thomsen, A. B., Kaltoft, M. S., Maislos, M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Blackwell Publishing Ltd 2016
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129465/
https://ncbi.nlm.nih.gov/pubmed/27381275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12736
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items